## **Product Datasheet**

### MyoD Antibody (MYOD1/3418R) [DyLight 650] NBP3-08543C

Unit Size: 100 ul

Store at 4C in the dark.

www.novusbio.com

technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP3-08543C

Updated 10/26/2023 v.20.1

# Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP3-08543C



#### NBP3-08543C

MyoD Antibody (MYOD1/3418R) [DyLight 650]

100 ul
Please see the vial label for concentration. If unlisted please contact technical services.
Store at 4C in the dark.
Monoclonal
MYOD1/3418R
0.05% Sodium Azide
IgG
DyLight 650
Protein A purified
50mM Sodium Borate
Rabbit
4654
MYOD1
Human
Rhabdomyosarcoma Marker
MyoD1, one of the MyoD family of myogenic helix-loop-helix transcription factors, combined with myogenin, plays a role in coordinating the myogenic differentiation pathway from the determination of mesodermal precursors into myoblasts, the differentiation of myoblasts into myotubes, and finally the
maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. Anti-MyoD1 immunostaining identifies cells committed to myogenesis in their earliest phase, thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, anti-MyoD1 may be used together with anti-Myogenin and anti-Desmin as a panel of markers since any RMS is virtually never negative for all three markers simultaneously.
maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. Anti-MyoD1 immunostaining identifies cells committed to myogenesis in their earliest phase, thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, anti-MyoD1 may be used together with anti-Myogenin and anti-Desmin as a panel of markers since any RMS is virtually
maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. Anti-MyoD1 immunostaining identifies cells committed to myogenesis in their earliest phase, thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, anti-MyoD1 may be used together with anti-Myogenin and anti-Desmin as a panel of markers since any RMS is virtually never negative for all three markers simultaneously. Recombinant fragment (around aa1-100) of human MyoD protein (exact
maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. Anti-MyoD1 immunostaining identifies cells committed to myogenesis in their earliest phase, thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, anti-MyoD1 may be used together with anti-Myogenin and anti-Desmin as a panel of markers since any RMS is virtually never negative for all three markers simultaneously. Recombinant fragment (around aa1-100) of human MyoD protein (exact sequence is proprietary) (Uniprot: P15172 )
maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. Anti-MyoD1 immunostaining identifies cells committed to myogenesis in their earliest phase, thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, anti-MyoD1 may be used together with anti-Myogenin and anti-Desmin as a panel of markers since any RMS is virtually never negative for all three markers simultaneously. Recombinant fragment (around aa1-100) of human MyoD protein (exact sequence is proprietary) (Uniprot: P15172 )
maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. Anti-MyoD1 immunostaining identifies cells committed to myogenesis in their earliest phase, thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, anti-MyoD1 may be used together with anti-Myogenin and anti-Desmin as a panel of markers since any RMS is virtually never negative for all three markers simultaneously. Recombinant fragment (around aa1-100) of human MyoD protein (exact sequence is proprietary) (Uniprot: P15172 ) DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.





#### Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

#### **Bio-Techne Canada**

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

#### **Bio-Techne Ltd**

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

#### **General Contact Information**

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

#### Products Related to NBP3-08543C

NBP2-24891C	Rabbit IgG Isotype Control [DyLight 650]
H00004654-P01-2ug	Recombinant Human MyoD GST (N-Term) Protein
291-G1-200	IGF-I/IGF-1 [Unconjugated]
H00004654-Q01-10ug	Recombinant Human MyoD GST (N-Term) Protein

#### Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP3-08543C

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

www.novusbio.com

